Click here to view online. Add this email to your safelist.

AstraZeneca logo

Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19

25 August 2020

The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of COVID-19.

The trial, called NCT04507256, will evaluate the safety, tolerability and pharmacokinetics of AZD7442. 

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2020

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.